Tag: Sanjiv Navangul
Budget 2025: Biotech stakeholders welcome focus on R&D, digitalization
Will the budget propel India's biotech industry toward becoming a global powerhouse, or are there gaps that need to be addressed? Here’s how the sector is responding.
BSV to set up a new biopharma manufacturing plant in Genome...
Proposed bio-pharmaceutical manufacturing facility will cater to domestic and export markets including regulated markets like USA and EU
Bharat Serums & Vaccines partners Sir JJ School of Arts to...
Sanjiv Navangul, Managing Director and CEO, BSV along with Vishwanath D. Sabale, Dean, Sir JJ School of Arts, felicitated the artists
Budget 2022: “Mention of Genomics & Pharma as sunrise opportunities is...
As the country moves towards good health and economic well-being, it is critical to continue to innovate in India and the rest of the world, says Sanjiv Navangul, Managing Director & CEO, Bharat Serums and Vaccines Limited................
Johnson & Johnson partners CSIR-IMTECH to develop new TB drugs
Memorandum of Understanding brings together best scientists from India and Johnson & Johnson to increase level and accelerate pace of innovation needed to make Tuberculosis history.......